Site icon OncologyTube

Immunotherapy Not Recommended Outside Trials Pembrolizumab for Microsatellite Instability or MMR

Sara A Hurvitz, MD, FACP Associate Professor of Medicine Director, Breast Oncology, shares Immunotherapy Not Recommended Outside Trials Pembrolizumab for Microsatellite Instability or MMR at the 2018 Oncology Summit in Huntington Beach, CA

Go to: http://www.moasc.org for more information

Exit mobile version